The effect of macrolide resistance on the presentation and outcome of patients hospitalized for streptococcus pneumoniae pneumonia

American Journal of Respiratory and Critical Care Medicine

Volumn 191, Issue 11, 2015, Pages 1265-1272

  Cilloniz, Catia ^a   Albert, Richard K ^b,c   Liapikou, Adamanthia ^d   Gabarrus, Albert ^a   Rangel, Ernesto ^e   Bello, Salvador ^f   Marco, Francesc ^g   Mensa, Josep ^g   Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d SOTIRIA GENERAL HOSPITAL   (Greece)

^e UNIVERSIDAD AUTÓNOMA DE NAYARIT   (Mexico)

^f HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

Author keywords

Community acquired pneumonia; Pneumococcal pneumonia; Pneumonia; Streptococcus pneumoniae resistant to macrolide

Indexed keywords

CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CLINDAMYCIN; ERYTHROMYCIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIUM CULTURE; FEMALE; FEVER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG COMPLICATION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PNEUMONIA SEVERITY INDEX; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; AGED; COMMUNITY-ACQUIRED INFECTIONS; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UTILIZATION;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; LENGTH OF STAY; MACROLIDES; MALE; MIDDLE AGED; PNEUMONIA, PNEUMOCOCCAL; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84930424264     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201502-0212OC     Document Type: Article

References (36)

1. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-3862.
2. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care associated pneumonia and community-acquired pneumonia: a single center experience. Antimicrob Agents Chemother 2007;51:3568-3573.
3. Welte T, Köhnlein T. Global and local epidemiology of community-acquired pneumonia: the experience of the CAPNETZ Network. Semin Respir Crit Care Med 2009;30:127-135.
4. Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, Manresa F, Gudiol F. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007;167:1393-1399.
5. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al.; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72.
6. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, Choudhury G, Hill AT. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011;53:107-113.
7. Jenkins SG, Farrell DJ. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 2009;15:1260-1264.
8. Van Bambeke F, Reinert RR, Appelbaum PC, Tulkens PM, Peetermans WE. Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options. Drugs 2007;67:2355-2382.
9. Felmingham D, Cantón R, Jenkins SG. Regional trends in beta-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007;55:111-118.
10. Farrell DJ, Klugman KP, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr Infect Dis J 2007;26:123-128.
11. Farrell DJ, Jenkins SG, Brown SD, Patel M, Lavin BS, Klugman KP. Emergence and spread of Streptococcus pneumoniae with erm(B) and mef(A) resistance. Emerg Infect Dis 2005;11:851-858.
12. File TM Jr. Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 2006; 12:31-41.
13. Klugman KP, Lonks JR. Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis 2005;11:802-807.
14. Neuman MI, Kelley M, Harper MB, File TM Jr, Camargo CA Jr; EMNet Investigators. Factors associated with antimicrobial resistance and mortality in pneumococcal bacteremia. J Emerg Med 2007;32: 349-357.
15. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify lowrisk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
16. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382.
17. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307:2526-2533.
18. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
19. Moreno S, García-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quirós JC, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis 1995;20:1195-1200.
20. Aspa J, Rajas O, Rodríguez de Castro F, Blanquer J, Zalacain R, Fenoll A, de Celis R, Vargas A, Rodríguez Salvanés F, España PP, et al.; Pneumococcal Pneumonia in Spain Study Group. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis 2004;38:787-798.
21. Lujan M, Gallego M, Fontanals D, Mariscal D, Rello J. Prospective observational study of bacteremic pneumococcal pneumonia: effect of discordant therapy on mortality. Crit Care Med 2004;32:625-631.
22. Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, Chang HH, Kim SW, Lee H, Kim YS, et al.; Asian Network for Surveillance of Resistant Pathogens Study Group. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in Asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004;38:1570-1578.
23. Asadi L, Eurich DT, Gamble JM, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Guideline adherence and macrolides reduced mortality in outpatients with pneumonia. Respir Med 2012;106: 451-458.
24. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, Majumdar SR. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012;55: 371-380.
25. Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones. Chest 2007;131:466-473.
26. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, Morris AJ, Luna CM, Snydman DR, Ko WC, et al.; International Pneumococcal Study Group. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-444.
27. Caballero J, Rello J. Combination antibiotic therapy for community-acquired pneumonia. Ann Intensive Care 2011;1:48.
28. Sligl WI, Asadi L, Eurich DT, Tjosvold L, Marrie TJ, Majumdar SR. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 2014;42:420-432.
29. Garin N, GennéD, Carballo S, Chuard C, Eich G, Hugli O, Lamy O, Nendaz M, Petignat PA, Perneger T, et al. b-Lactam monotherapy vs b-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014;174:1894-1901.
30. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents 2008;31:12-20.
31. Restrepo MI, Mortensen EM, Waterer GW, Wunderink RG, Coalson JJ, Anzueto A. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009;33:153-159.
32. Shortridge VD, Doern GV, Brueggemann AB, Beyer JM, Flamm RK. Prevalence of macrolide resistance mechanisms in Streptococcus pneumoniae isolates from a multicenter antibiotic resistance surveillance study conducted in the United States in 1994-1995. Clin Infect Dis 1999;29:1186-1188.
33. Ewig S, Ruiz M, Torres A, Marco F, Martinez JA, Sanchez M, Mensa J. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159: 1835-1842.
34. Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echagüen A, Gareen IF, Reiss PT, Medeiros AA. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556-564.
35. Pérez-Trallero E, García-de-la-Fuente C, García-Rey C, Baquero F, Aguilar L, Dal-Ré R, García-de-Lomas J; Spanish Surveillance Group for Respiratory Pathogens. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005;49:1965-1972.
36. Daneman N, McGeer A, Green K, Low DE; Toronto Invasive Bacterial Diseases Network. Macrolide resistance in bacteremic pneumococcal disease: implications for patient management. Clin Infect Dis 2006;43:432-438.